---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000364"
form_type: "8-K/A"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T20:02:58.255734+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider

## Summary
- Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.
- Updated net loss: FY2023 $29.7M ($1.12 per share); Q4 2023 $11.7M ($0.44 per share).
- Adjustments are non-cash: deferred revenue increased $3.2M, offset by reduction in stockholders' equity.
- Cash, equivalents, restricted cash and cash runway unchanged.
- Annual Report on Form 10-K for FY2023 filed March 14, 2024.

## SEC filing metadata
- accession: 0001193805-24-000364
- form_type: 8-K/A
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/e619365_8ka-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000364
- JSON: https://secwatch.observer/filing/0001193805-24-000364.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000364.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported fiscal fourth quarter 2023 results: revenue $25.0, net income $11.7 million, EPS $0.44 per share.
  - Period: fiscal fourth quarter 2023
  - Revenue: $25.0
  - Net income: $11.7 million
  - EPS: $0.44 per share
  - Result: reported results
  source text: the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported fiscal year ended December 31, 2023 results: revenue $157.7 million, net income $29.7 million, EPS $1.12 per share.
  - Period: fiscal year ended December 31, 2023
  - Revenue: $157.7 million
  - Net income: $29.7 million
  - EPS: $1.12 per share
  - Result: reported results
  source text: the changes affected the fiscal fourth quarter only and resulted in a decrease in collaboration revenue from $160.9 million to $157.7 million for the fiscal year-end and $28.2 million to $25.0 for the fiscal fourth quarter 2023. This $3.2 million adjustment resulted in an updated net loss of $29.7 million, or $1.12 per share, and $11.7 million, or $0.44 per share, for the fiscal year end and fourth quarter end 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.